Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510023 · ClinicalTrials.gov registry record · NA
Rewards Sensitivity After Brain Injury
A NA study, sponsored by Shirley Ryan AbilityLab.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT06510023: Completed NA study, sponsored by Shirley Ryan AbilityLab.
NCT06510023 is a NA study that has completed, run by Shirley Ryan AbilityLab. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06510023, a NA study, has completed, sponsored by Shirley Ryan AbilityLab.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
A study measuring rewards sensitivity in individuals with acquired brain injury at an acute rehabilitation level.
Primary Outcome
Accuracy (percentage of correct responses) in a Cued Response Reaction task
Interventions
- BEHAVIORAL Type of reward presented
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-03-21 |
| Est. Completion | 2022-03-20 |
| Phase | NA |
What the finished NCT06510023 record still lists
NCT06510023 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Type of reward presented is the first listed.
NCT06510023 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06510023 about?
NCT06510023 is a clinical study titled "Rewards Sensitivity After Brain Injury". A study measuring rewards sensitivity in individuals with acquired brain injury at an acute rehabilitation level.
What is the current status of trial NCT06510023?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2021-03-21. Estimated completion is 2022-03-20.
What interventions are being tested in trial NCT06510023?
The interventions under investigation include: Type of reward presented (BEHAVIORAL).
Who is sponsoring clinical trial NCT06510023?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06510023's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI